


JO19 Rec'd PCT/PTO 13 JUN 2001

| | | |
|--|---|--|
| FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV. 5-93) | | ATTORNEY'S DOCKET NUMBER A3400PCT-US U.S. APPLICATION NO. (If known, enter 37 C.F.R. 1.53) 097868026 |
| TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 | | |
| INTERNATIONAL APPLICATION NO. PCT/IB00/00165 | INTERNATIONAL FILING DATE 5 January 2000 | PRIORITY DATE CLAIMED U.S. No. 60/114,758 (05.01.99) |
| TITLE OF INVENTION HUMAN ADULT ASTROCYTES, THEIR PREPARATION AND USES THEREOF | | |
| APPLICANT(S) FOR DO/EO/US Ridet, Jean-Luc; and MALLET, Jacques | | |
| Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: | | |
| 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)), and Power of Attorney (unexecuted). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. Below concern other document(s) or information included: 11. <input type="checkbox"/> An information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input type="checkbox"/> Other items or information | | |
| CERTIFICATION UNDER 37 CFR 1.10 | | |
| "Express Mail" Mailing Number EL68515422US I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated Above and is addressed to Box PCT, Assistant Commissioner for Patent, Washington, D.C. 20231, Attn: EO/US <u>William C. Coppola</u> (Type or print name of person mailing paper) | | Date of Deposit June 14, 2001  (Signature of person mailing paper) |

[illegible]

HUMAN ADULT ASTROCYTES, THEIR PREPARATION AND USES THEREOF

Field of the Invention

This invention relates to the field of neurobiology. More specifically, it relates
5 to purified human adult astrocytes, to methods for their preparation, and to their use,
especially for the treatment of neurodegenerative disorders or trauma to the central
nervous system.

Background of the Invention

10

Astrocytes

The combination of cell transplantation and gene transfer techniques provides a
therapeutic approach to neurodegenerative diseases and traumatic injury. Several cell
types, e.g. progenitor cells, neurons, glial cells, fibroblasts and myoblasts, have been
15 investigated as vehicles for gene delivery to the central nervous system (CNS) (Wolff et
al., 1989; Horellou et al., 1990a,b; Fisher et al., 1991, 1993, Gage et al., 1995; Sabate et
al., 1995; Fisher, 1997; Martinez-Serrano and Bjorklund, 1997). Particular attention has
been paid to the therapeutic activity of genetically engineered astrocytes (Cunningham et
al., 1991, 1994; La Gamma et al., 1993; Castillo et al., 1994; Pundt et al., 1995;
20 Lundberg et al., 1996; Lin et al., 1997). Astrocytes are especially targeted for brain
repair because they are normal CNS constituents, are endowed with efficient secretory
mechanisms and provide support to neurons through the release of trophic factors that
promote their survival, differentiation and regeneration. In addition, they can be
expanded in culture and genetically engineered to express foreign transgenes. Recently,
25 human fetal astrocytes arising from legal abortions have been cultured and successfully
transduced with a retrovirus driving the expression of active NGF (Lin et al., 1997).

Human adult astrocytes are more relevant for human brain repair, since they
allow autologous *ex vivo* gene transfer, thus obviating immunological rejection and side
effects of immunosuppressors. In recent studies that attempted to culture human adult
30 astrocytes, contamination with microglial cells was reported (Yong et al., 1991, 1992).

Gene Therapy

Ex vivo gene transfer involves the delivery of therapeutic cells to a patient (Wolff et al., 1989; Horellou et al., 1990a,b; Fisher et al., 1991, 1993, Gage et al., 1995; Sabate et al., 1995; Fisher, 1997; Martinez-Serrano and Bjorklund, 1997; Taylor, 1997). The use of immortalized cell lines for gene therapy is of limited value, since they retain tumorigenic properties. In contrast, primary cultured cells are more suitable. One of the best cell types for *ex vivo* gene transfer and subsequent transplantation is astrocytes (La Gamma et al., 1993; Castillo et al., 1994; Cunningham et al., 1994; Ridoux et al., 1994; Pundt et al., 1995; Lundberg et al., 1996; Lin et al., 1997), which are normally present in the CNS as the major supporting cells with efficient secretory machinery. Grafted astrocytes, previously modified to produce enzymes, neurotransmitters or trophic factors, can integrate and function suitably in the CNS (see refs in Taylor, 1997). Rat primary cultured astrocytes have been genetically engineered to produce NGF and BDNF, and survive after transplantation into the brain (Cunningham et al., 1991, 1994; Yoshimoto et al., 1995).

Recently, the interest in human astrocytes has grown (Yong et al., 1991, 1992; Aloisi et al., 1992; Perzelova and Mares, 1993; Pundt et al., 1995; Lin et al. 1997). Yong and colleagues (1992) reported that up to 80% of primary cultured cells were macrophages/microglial cells. After removal of most of the oligodendrocytes and microglial cells, 70% of the cells were astrocytes (Yong et al., 1992). The presence of microglial cells in astrocyte cultures may cause undesirable effects both *in vitro* and *in vivo*, since they proliferate actively and are major components of the immune cell population. Therefore, there is a need for a method to produce a population of astrocytes that is free of contaminating microglial cells. The present invention addresses this need, as discussed below. The present invention overcomes the disadvantages of impure preparations of astrocytes, and provides a cell preparation suitable for treating trauma to the CNS and for the treatment of neurodegenerative disorders, such as Parkinson's, Huntington's or Alzheimer's disease.

The citation of any reference herein should not be construed as an admission that such reference is available as "Prior Art" to the instant application.

Summary of the Invention

The present invention provides purified astrocytes and methods for their
5 preparation. In a preferred embodiment, the astrocytes are human, adult astrocytes.

Therefore, the invention provides a method of producing an essentially pure
population of astrocytes comprising: a) introducing a preparation of astrocytes to a
culture vessel, b) incubating the astrocytes from step a) under conditions enabling
attachment of the astrocytes to the culture vessel, and c) removing cells which have not
10 attached to the culture vessel at a time of about 48 hours from the beginning of step a).
By being "essentially pure" the cell population is at least 75% astrocytes, preferably at
least 85% astrocytes, more preferably at least about 95% astrocytes, and most preferably
greater than about 98% astrocytes. The term "about" means within 20%, preferably
within 10%, and more preferably within 5% of a given value or range. A "culture
15 vessel" can be any support suitable for cell attachment and growth including, but not
limited to, a culture dish or flask.

In a preferred embodiment, the astrocytes are human astrocytes. More
preferably, they are human adult astrocytes.

Astrocytes produced according to the present invention are essentially free of
20 microglial cells. That is, the presence of microglial cells is not detected by OX42
immunostaining and labeling with B₄ isolectin from *Griffonia simplicifolia*.

In one aspect of the method of the invention, an exogenous nucleic acid may be
introduced into the astrocytes. The nucleic acid may be introduced into the astrocytes
with a viral vector, by calcium-phosphate precipitation, liposome-mediated transfection,
25 cationic lipid transfection, or lipopolyamine-mediated transfection. Preferably, the
nucleic acid encodes a neuroactive substance.

The invention also provides an essentially pure population of astrocytes.
Preferably, the astrocytes are human astrocytes. More preferably, they are human adult
astrocytes. A population of astrocytes produced according to the present invention is
30 essentially free of microglial cells.

In one aspect of the invention, the population of astrocytes comprises an
exogenous nucleic acid. In a preferred embodiment, the nucleic acid encodes a

neuroactive substance. The nucleic acid may be DNA or RNA. In one aspect, the nucleic acid is a DNA encoding a protein, polypeptide or peptide. The protein, polypeptide or peptide may be a growth factor, neurotrophic factor, or enzyme. Alternatively, the nucleic acid may be a DNA encoding an antisense-RNA or a ribozyme. In a preferred embodiment, the nucleic acid is operably linked to a regulatory region comprising a regulatable promoter, an inducible promoter, a neural cell-specific promoter or a viral promoter.

The present invention also provides an implant comprising a population of essentially pure astrocytes. The invention further provides a composition comprising an essentially pure population of astrocytes comprising an exogenous nucleic acid encoding a neuroactive substance.

These and other objects are addressed by this invention, which is explained in greater detail in the attached drawings and the following Detailed Description and Examples.

Brief Description of the Drawings

Figure 1: Primary culture from human adult cerebral cortex.

(A), Phase contrast micrographs showing low magnification (x70) of primary cultures of human adult astrocytes. (B), Higher magnification (x560) of a dividing flat cell at telophasis stage.

Figure 2: Immunocytochemical characterization of primary cultures of human adult astrocytes.

Low magnification (x280) micrographs illustrating that all the cells were GFAP- (A) and S100 β -positive (B).

Figure 3: *In vitro* proliferation of human adult astrocytes.

Proliferation rates are expressed as percent of increase in cell number since t_0 . Human adult astrocytes proliferated *in vitro* when cultured in FCS. Note that the cells proliferated twice as fast when cultured in the presence of 20% FCS than in 10% FCS (A). NGF and bFGF (50 ng/ml) did not have any mitogenic effects on primary cultured

human adult astrocytes (B). Note that when HS was added to the medium, most of the cells did not attach onto the culture dish and they were removed with the medium.

Figure 4: TH immunocytochemistry after adenoviral transduction of human adult astrocytes.

(B), Low magnification (x70) micrographs illustrating that 50-60% of the cells were TH-positive one week post-infection (A, non-infected cells). (C), Higher magnification (x560) illustrating transduced astrocytes containing hTH.

Figure 5: TH activity in transduced human adult astrocytes


TH activity was detected within the first week post-infection and then increased to 35650 pmol [³H] H₂O/mg prot./h on day 14. Note that TH activity decreased by at least 10 fold in the presence of doxycycline 14 days post-infection.

Detailed Description of the Invention

Definitions

The following defined terms are used throughout the present specification, and should be helpful in understanding the scope and practice of the present invention.

A “**polypeptide**” is a polymeric compound comprised of covalently linked amino acid residues. Amino acids have the following general structure:



Amino acids are classified into seven groups on the basis of the side chain R: (1) aliphatic side chains, (2) side chains containing a hydroxylic (OH) group, (3) side chains containing sulfur atoms, (4) side chains containing an acidic or amide group, (5) side

chains containing a basic group, (6) side chains containing an aromatic ring, and (7) proline, an imino acid in which the side chain is fused to the amino group.

A "**protein**" is a polypeptide which plays a structural or functional role in a living cell.

5 The polypeptides and proteins of the invention may be glycosylated or unglycosylated.

 A "**variant**" of a polypeptide or protein is any analogue, fragment, derivative, or mutant which is derived from a polypeptide or protein and which retains at least one biological property of the polypeptide or protein. Different variants of the polypeptide
10 or protein may exist in nature. These variants may be allelic variations characterized by differences in the nucleotide sequences of the structural gene coding for the protein, or may involve differential splicing or post-translational modification. The skilled artisan can produce variants having single or multiple amino acid substitutions, deletions, additions, or replacements. These variants may include, inter alia: (a) variants in which
15 one or more amino acid residues are substituted with conservative or non-conservative amino acids, (b) variants in which one or more amino acids are added to the polypeptide or protein, (c) variants in which one or more of the amino acids includes a substituent group, and (d) variants in which the polypeptide or protein is fused with another polypeptide such as serum albumin. The techniques for obtaining these variants,
20 including genetic (suppressions, deletions, mutations, etc.), chemical, and enzymatic techniques, are known to persons having ordinary skill in the art.

 If such allelic variations, analogues, fragments, derivatives, mutants, and modifications, including alternative mRNA splicing forms and alternative post-translational modification forms result in derivatives of the polypeptide which retain any
25 of the biological properties of the polypeptide, they are intended to be included within the scope of this invention.

 A "**nucleic acid**" is a polymeric compound comprised of covalently linked subunits called nucleotides. Nucleic acid includes polyribonucleic acid (RNA) and polydeoxyribonucleic acid (DNA), both of which may be single-stranded or double-
30 stranded. DNA includes cDNA, genomic DNA, synthetic DNA, and semi-synthetic DNA. The sequence of nucleotides that encodes a protein is called the sense sequence.

An "exogenous nucleic acid" is genetic material which has been introduced into a cell not naturally containing the nucleic acid sequence.

"Regulatory region" means a nucleic acid sequence which regulates the expression of a second nucleic acid sequence. A regulatory region may include sequences which are naturally responsible for expressing a particular nucleic acid (a homologous region) or may include sequences of a different origin (responsible for expressing different proteins or even synthetic proteins). In particular, the sequences can be sequences of eukaryotic or viral genes or derived sequences which stimulate or repress transcription of a gene in a specific or non-specific manner and in an inducible or non-inducible manner. Regulatory regions include origins of replication, RNA splice sites, enhancers, transcriptional termination sequences, signal sequences which direct the polypeptide into the secretory pathways of the target cell, and promoters.

A regulatory region from a "heterologous source" is a regulatory region which is not naturally associated with the expressed nucleic acid. Included among the heterologous regulatory regions are regulatory regions from a different species, regulatory regions from a different gene, hybrid regulatory sequences, and regulatory sequences which do not occur in nature, but which are designed by one having ordinary skill in the art.

A "vector" is any means for the transfer of a nucleic acid of interest into a host cell. The term "vector" includes both viral and nonviral means for introducing the nucleic acid into a cell *in vitro*, *ex vivo* or *in vivo*. Non-viral vectors include plasmids, liposomes, electrically charged lipids (cytofectins), DNA-protein complexes, and biopolymers. Viral vectors include retrovirus, adeno-associated virus, pox, baculovirus, vaccinia, herpes simplex, Epstein-Barr and adenovirus vectors. A nucleic acid may contain one or more regulatory regions, and/or selectable markers useful in selecting, measuring, and monitoring nucleic acid transfer results (transfer to which tissues, duration of expression, etc.).

"Pharmaceutically acceptable carrier" includes diluents and fillers which are pharmaceutically acceptable for methods of administration, are sterile, and may be aqueous or oleaginous suspensions formulated using suitable dispersing or wetting agents and suspending agents. The particular pharmaceutically acceptable carrier and the ratio of active compound to carrier are determined by the solubility and chemical

properties of the composition, the particular mode of administration, and standard pharmaceutical practice.

Astrocytes

5 One aspect of the present invention is to provide a population of essentially pure human astrocyte cells. The purified cells may contain introduced genetic material encoding a product of interest. Another aspect of the instant invention is to provide human adult astrocytes having desired therapeutic properties, and suitable for *ex vivo* cell therapy. Transplantation of genetically modified human cells to rat brain is
10 disclosed in Sabate et al. (Nature Genetics, Volume 9, pp. 256-260 (1995)), the entire contents of which are incorporated herein by reference.

The present invention now provides a very efficient way to obtain high purity adult human astrocytes, capable of producing factors with biological effect, such as neuroactive substances for *ex vivo* gene therapy. The inventors have now found
15 conditions that enable successful purification, amplification, and *in vitro* modification of these cells. Substantial levels of gene expression were obtained in cells modified with a recombinant adenovirus. Genetically modified astrocytes enables gene therapy of neurodegenerative diseases and of trauma to the CNS.

The combination of gene transfer techniques and cell transplantation provides an
20 approach to deliver therapeutic molecules into the CNS. Astrocytes are particularly well suited for CNS therapy because of their CNS origin, their efficient secretory mechanisms and their role as neuronal support. Most importantly, the use of human adult astrocytes as cellular vehicles for *ex vivo* gene transfer opens the way to autologous transplantation, thus obviating immunological rejection and the side effects of immunosuppressors. As
25 provided herein, these cells can be purified, expanded and genetically modified *in vitro*. Astrocytes derived from human adult cerebral cortex have been grown and maintained *in vitro* as pure primary cultures for at least 10 months. In addition, cells are efficiently transduced by viral vectors encoding a neuroactive substance. When the neuroactive substance is human tyrosine hydroxylase (hTH) under the negative control of the
30 tetracycline-based regulatory system (tet-off), the infected cells synthesize large amounts of active hTH and release L-Dopa. In addition, doxycycline, a potent analog of tetracycline, efficiently regulates transgene expression.

Vectors

As discussed above, a "vector" is any means for the transfer of a nucleic acid according to the invention into a host cell. Preferred vectors are viral vectors, such as retroviruses, herpes viruses, adenoviruses, and adeno-associated viruses. Thus, a gene comprising a nucleic acid of interest is introduced *in vivo*, *ex vivo*, or *in vitro* using a viral vector or through direct introduction of DNA. Expression in targeted tissues can be effected by targeting the transgenic vector to specific cells, such as with a viral vector or a receptor ligand, or by using a tissue-specific promoter, or both.

Viral vectors commonly used for *in vivo* or *ex vivo* targeting and therapy procedures are DNA-based vectors and retroviral vectors. Methods for constructing and using viral vectors are known in the art [see, e.g., Miller and Rosman, *BioTechniques* 7:980-990 (1992)]. Preferably, the viral vectors are replication defective, that is, they are unable to replicate autonomously in the target cell. In general, the genome of the replication defective viral vectors which are used within the scope of the present invention lack at least one region which is necessary for the replication of the virus in the infected cell. These regions can either be eliminated (in whole or in part), be rendered non-functional by any technique known to a person skilled in the art. These techniques include the total removal, substitution (by other sequences, in particular by the inserted nucleic acid), partial deletion or addition of one or more bases to an essential (for replication) region. Such techniques may be performed *in vitro* (on the isolated DNA) or *in situ*, using the techniques of genetic manipulation or by treatment with mutagenic agents. Preferably, the replication defective virus retains the sequences of its genome which are necessary for encapsulating the viral particles.

DNA viral vectors include an attenuated or defective DNA virus, such as but not limited to herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), vaccinia virus, and the like. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. Defective virus is not replication competent after introduction into a cell, and thus does not lead to a productive viral infection. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Thus, a specific tissue can be specifically targeted. Examples of particular vectors include, but are not limited to, a

defective herpes virus 1 (HSV1) vector [Kaplitt et al., *Molec. Cell. Neurosci.* 2:320-330 (1991)], defective herpes virus vector lacking a glyco-protein L gene [Patent Publication RD 371005 A], or other defective herpes virus vectors [International Patent Publication No. WO 94/21807, published September 29, 1994; International Patent Publication No. WO 92/05263, published April 2, 1994]; an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet et al. [*J. Clin. Invest.* 90:626-630 (1992); *see also* La Salle et al., *Science* 259:988-990 (1993)]; and a defective adeno-associated virus vector [Samulski et al., *J. Virol.* 61:3096-3101 (1987); Samulski et al., *J. Virol.* 63:3822-3828 (1989); Lebkowski et al., *Mol. Cell. Biol.* 8:3988-3996 (1988)].

Preferably, for *in vivo* administration, an appropriate immunosuppressive treatment is employed in conjunction with the viral vector, *e.g.*, adenovirus vector, to avoid immunodeactivation of the viral vector and transfected cells. For example, immunosuppressive cytokines, such as interleukin-12 (IL-12), interferon- γ (IFN- γ), or anti-CD4 antibody, can be administered to block humoral or cellular immune responses to the viral vectors [*see, e.g.*, Wilson, *Nature Medicine* (1995)]. In addition, it is advantageous to employ a viral vector that is engineered to express a minimal number of antigens.

Naturally, the invention contemplates delivery of a vector to astrocytes that will express a therapeutically effective amount of a gene of interest for gene therapy applications. The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50 percent, more preferably by at least 90 percent, and most preferably prevent, a clinically significant deficit in the activity, function and response of the host. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the host.

Any vector, viral or non-viral, of the invention will preferably be introduced *ex vivo* to astrocytes in a pharmaceutically acceptable vehicle or carrier. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in

humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.

Adenovirus vectors

In a preferred embodiment, the vector is an adenovirus vector. Adenoviruses are eukaryotic DNA viruses that can be modified to efficiently deliver a nucleic acid of the invention to a variety of cell types. Various serotypes of adenovirus exist. Of these serotypes, preference is given, within the scope of the present invention, to using type 2 or type 5 human adenoviruses (Ad 2 or Ad 5) or adenoviruses of animal origin (see WO94/26914). Those adenoviruses of animal origin which can be used within the scope of the present invention include adenoviruses of canine, bovine, murine (example: Mav1, Beard et al., Virology 75 (1990) 81), ovine, porcine, avian, and simian (example: SAV) origin. Preferably, the adenovirus of animal origin is a canine adenovirus, more preferably a CAV2 adenovirus (e.g. Manhattan or A26/61 strain (ATCC VR-800), for example).

Preferably, the replication defective adenoviral vectors of the invention comprise the ITRs, an encapsidation sequence and the nucleic acid of interest. Still more preferably, at least the E1 region of the adenoviral vector is non-functional. The deletion in the E1 region preferably extends from nucleotides 455 to 3329 in the sequence of the Ad5 adenovirus (PvuII-BglII fragment) or 382 to 3446 (HinfII-Sau3A fragment). Other regions may also be modified, in particular the E3 region (WO95/02697), the E2 region (WO94/28938), the E4 region (WO94/28152, WO94/12649 and WO95/02697), or in any of the late genes L1-L5.

In a preferred embodiment, the adenoviral vector has a deletion in the E1 region (Ad 1.0). Examples of E1-deleted adenoviruses are disclosed in EP 185,573, the contents of which are incorporated herein by reference. In another preferred embodiment, the adenoviral vector has a deletion in the E1 and E4 regions (Ad 3.0). Examples of E1/E4-deleted adenoviruses are disclosed in WO95/02697 and WO96/22378, the contents of which are incorporated herein by reference. In still another preferred embodiment, the adenoviral

vector has a deletion in the E1 region into which the E4 region and the nucleic acid sequence are inserted (see FR94 13355, the contents of which are incorporated herein by reference).

The replication defective recombinant adenoviruses according to the invention can be prepared by any technique known to the person skilled in the art (Levrero et al., Gene 101 (1991) 195, EP 185 573; Graham, EMBO J. 3 (1984) 2917). In particular, they can be prepared by homologous recombination between an adenovirus and a plasmid which carries, inter alia, the DNA sequence of interest. The homologous recombination is effected following cotransfection of the adenovirus and plasmid into an appropriate cell line. The cell line which is employed should preferably (i) be transformable by the said elements, and (ii) contain the sequences which are able to complement the part of the genome of the replication defective adenovirus, preferably in integrated form in order to avoid the risks of recombination. Examples of cell lines which may be used are the human embryonic kidney cell line 293 (Graham et al., J. Gen. Virol. 36 (1977) 59) which contains the left-hand portion of the genome of an Ad5 adenovirus (12%) integrated into its genome, and cell lines which are able to complement the E1 and E4 functions, as described in applications WO94/26914 and WO95/02697. Recombinant adenoviruses are recovered and purified using standard molecular biological techniques, which are well known to one of ordinary skill in the art.

Adeno-associated virus vectors

The adeno-associated viruses (AAV) are DNA viruses of relatively small size which can integrate, in a stable and site-specific manner, into the genome of the cells which they infect. They are able to infect a wide spectrum of cells without inducing any effects on cellular growth, morphology or differentiation, and they do not appear to be involved in human pathologies. The AAV genome has been cloned, sequenced and characterised. It encompasses approximately 4700 bases and contains an inverted terminal repeat (ITR) region of approximately 145 bases at each end, which serves as an origin of replication for the virus. The remainder of the genome is divided into two essential regions which carry the encapsulation functions: the left-hand part of the genome, which contains the rep gene involved in viral replication and expression of the viral genes; and the right-hand part of the genome, which contains the cap gene encoding the capsid proteins of the virus.

The use of vectors derived from the AAVs for transferring genes *in vitro* and *in vivo* has been described (see WO 91/18088; WO 93/09239; US 4,797,368, US 5,139,941, EP 488

528). These publications describe various AAV-derived constructs in which the rep and/or cap genes are deleted and replaced by a gene of interest, and the use of these constructs for transferring the said gene of interest in vitro (into cultured cells) or in vivo, (directly into an organism). The replication defective recombinant AAVs according to the invention can be prepared by cotransfecting a plasmid containing the nucleic acid sequence of interest flanked by two AAV inverted terminal repeat (ITR) regions, and a plasmid carrying the AAV encapsulation genes (rep and cap genes), into a cell line which is infected with a human helper virus (for example an adenovirus). The AAV recombinants which are produced are then purified by standard techniques.

The invention also relates, therefore, to an AAV-derived recombinant virus whose genome encompasses a sequence encoding a nucleic acid of interest flanked by the AAV ITRs. The invention also relates to a plasmid encompassing a sequence encoding a nucleic acid encoding an anti-angiogenic factor flanked by two ITRs from an AAV. Such a plasmid can be used as it is for transferring the nucleic acid sequence, with the plasmid, where appropriate, being incorporated into a liposomal vector (pseudo-virus).

Retrovirus vectors

In another embodiment the gene can be introduced in a retroviral vector, e.g., as described in Anderson et al., U.S. Patent No. 5,399,346; Mann et al., 1983, Cell 33:153; Temin et al., U.S. Patent No. 4,650,764; Temin et al., U.S. Patent No. 4,980,289; Markowitz et al., 1988, J. Virol. 62:1120; Temin et al., U.S. Patent No. 5,124,263; EP 453242, EP178220; Bernstein et al. Genet. Eng. 7 (1985) 235; McCormick, BioTechnology 3 (1985) 689; International Patent Publication No. WO 95/07358, published March 16, 1995, by Dougherty et al.; and Kuo et al., 1993, Blood 82:845. The retroviruses are integrating viruses which infect dividing cells. The retrovirus genome includes two LTRs, an encapsulation sequence and three coding regions (gag, pol and env). In recombinant retroviral vectors, the gag, pol and env genes are generally deleted, in whole or in part, and replaced with a heterologous nucleic acid sequence of interest. These vectors can be constructed from different types of retrovirus, such as, HIV, MoMuLV ("murine Moloney leukaemia virus" MSV ("murine Moloney sarcoma virus"), HaSV ("Harvey sarcoma virus"); SNV ("spleen necrosis virus"); RSV ("Rous sarcoma virus") and Friend virus. Defective retroviral vectors are disclosed in WO95/02697.

In general, in order to construct recombinant retroviruses containing a nucleic acid sequence, a plasmid is constructed which contains the LTRs, the encapsulation sequence and the coding sequence. This construct is used to transfect a packaging cell line, which cell line is able to supply in trans the retroviral functions which are deficient in the plasmid. In general, the packaging cell lines are thus able to express the gag, pol and env genes. Such packaging cell lines have been described in the prior art, in particular the cell line PA317 (US4,861,719); the PsiCRIP cell line (WO90/02806) and the GP+envAm-12 cell line (WO89/07150). In addition, the recombinant retroviral vectors can contain modifications within the LTRs for suppressing transcriptional activity as well as extensive encapsulation sequences which may include a part of the gag gene (Bender et al., J. Virol. 61 (1987) 1639). Recombinant retroviral vectors are purified by standard techniques known to those having ordinary skill in the art.

Retroviral vectors can be constructed to function as infectious particles or to undergo a single round of transfection. In the former case, the virus is modified to retain all of its genes except for those responsible for oncogenic transformation properties, and to express the heterologous gene. Non-infectious viral vectors are prepared to destroy the viral packaging signal, but retain the structural genes required to package the co-introduced virus engineered to contain the heterologous gene and the packaging signals. Thus, the viral particles that are produced are not capable of producing additional virus.

Targeted gene delivery is described in International Patent Publication WO 95/28494, published October 1995.

Non-viral vectors

Alternatively, the vector can be introduced to astrocytes by lipofection. For the past decade, there has been increasing use of liposomes for encapsulation and transfection of nucleic acids *in vitro*. Synthetic cationic lipids designed to limit the difficulties and dangers encountered with liposome mediated transfection can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker [Felgner, et. al., *Proc. Natl. Acad. Sci. U.S.A.* 84:7413-7417 (1987); see Mackey, et al., *Proc. Natl. Acad. Sci. U.S.A.* 85:8027-8031 (1988); Ulmer et al., *Science* 259:1745-1748 (1993)]. The use of cationic lipids may promote encapsulation of negatively charged nucleic acids, and also promote fusion with negatively charged cell membranes [Felgner and Ringold, *Science* 337:387-388 (1989)]. Particularly useful lipid compounds and compositions for transfer of nucleic acids are described in

International Patent Publications WO95/18863 and WO96/17823, and in U.S. Patent No. 5,459,127. The use of lipofection to introduce exogenous genes into specific cells *ex vivo* has certain practical advantages. Molecular targeting of liposomes to specific cells represents one area of benefit. Lipids may be chemically coupled to other molecules for the purpose of targeting [see Mackey, et. al., *supra*]. Targeted peptides, *e.g.*, hormones or neurotransmitters, and proteins such as antibodies, or non-peptide molecules could be coupled to liposomes chemically.

Other molecules are also useful for facilitating transfection of a nucleic acid, such as a cationic oligopeptide (*e.g.*, International Patent Publication WO95/21931), peptides derived from DNA binding proteins (*e.g.*, International Patent Publication WO96/25508), or a cationic polymer (*e.g.*, International Patent Publication WO95/21931).

It is also possible to introduce the vector as a naked DNA plasmid. Naked DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, *e.g.*, transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter [see, *e.g.*, Wu et al., *J. Biol. Chem.* 267:963-967 (1992); Wu and Wu, *J. Biol. Chem.* 263:14621-14624 (1988); Hartmut et al., Canadian Patent Application No. 2,012,311, filed March 15, 1990; Williams et al., *Proc. Natl. Acad. Sci. USA* 88:2726-2730 (1991)]. Receptor-mediated DNA delivery approaches can also be used [Curiel et al., *Hum. Gene Ther.* 3:147-154 (1992); Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)].

Nucleic Acids

Genetic modification and grafting of astrocytes enables their use in numerous applications, depending on the introduced genetic material.

Reporter genes, such as the *Lac Z* gene, may help to solve important scientific questions in the field of neural development. In particular, the potential of progenitors explanted from various zones of the brain to survive and differentiate independently of their origin could be investigated by following them after grafting in various zones of developing or adult brains.

Nucleic acids comprising a therapeutic gene are of particular interest. These genes include any gene encoding a neuroactive substance; a substance capable of

exerting a beneficial effect on cells of the central nervous system. It may be a substance capable of compensating for a deficiency in or of reducing an excess of an endogenous substance. Alternatively, it may be a substance conferring new properties on the cells.

5 The neuroactive substance may be an antisense sequence, a polypeptide or a protein. Among the polypeptides and proteins suitable for practice of the invention are growth factors, neurotrophic factors, cytokines, neurotransmitters, enzymes, neurotransmitter receptors and hormone receptors.

Preferably, the growth factor is a colony stimulating factor (G-CSF, GM-CSF, M-CSF, CSF, and the like), endothelial cell growth factor (ECGF, FGF1), fibroblast
10 growth factor (aFGFa, bFGF) or vascular cell growth factor (VEGF). Among the neurotrophic factors, the preferred factors are ciliary neurotrophic factor (CNTF), glial cell maturation factors (GMFa, b), GDNF, BDNF, NT-3, NT-5 and the like. The complete nucleotide sequence encoding NT-3 is disclosed in WO91/03569, the contents of which are incorporated herein by reference.

15 Preferred cytokines are the interleukins and interferons. Enzymes included within the scope of the invention are the enzymes for the biosynthesis of neurotransmitters (tyrosine hydroxylase, acetylcholine transferase, glutamic acid decarboxylase) and the lysosomal enzymes (hexosaminidases, arylsulphatase, glucocerebrosidase, HGPRT). The enzymes involved in the detoxification of free
20 radicals (super oxide dismutase I, II or III, catalase, glutathione peroxidase) are preferred. Receptors include the androgen receptors (involved in Kennedy's disease).

These proteins may be used in native form, or in the form of a variant or fragment thereof.

The neuroactive substance may also be an antisense sequence. The down
25 regulation of gene expression using antisense nucleic acids can be achieved at the translational or transcriptional level. Antisense nucleic acids of the invention are preferably nucleic acid fragments capable of specifically hybridizing with a nucleic acid encoding an endogenous neuroactive substance or the corresponding messenger RNA. These antisense nucleic acids can be synthetic oligonucleotides, optionally modified to
30 improve their stability and selectivity. They can also be DNA sequences whose expression in the cell produces RNA complementary to all or part of the mRNA encoding an endogenous neuroactive substance. Antisense nucleic acids can be prepared

by expression of all or part of a nucleic acid encoding an endogenous neuroactive substance, in the opposite orientation, as described in EP 140308. Any length of antisense sequence is suitable for practice of the invention so long as it is capable of down-regulating or blocking expression of the endogenous neuroactive substance.

- 5 Preferably, the antisense sequence is at least 20 nucleotides in length. The preparation and use of antisense nucleic acids, DNA encoding antisense RNAs and the use of oligo and genetic antisense is disclosed in WO92/15680, the contents of which are incorporated herein by reference.

- The nucleic acid may be of natural or artificial origin. It may be especially
10 genomic DNA (gDNA), complementary DNA (cDNA), hybrid sequences or synthetic or semisynthetic sequences. It may be of human, animal, plant, bacterial or viral origin and the like. It may be obtained by any technique known to persons skilled in the art, and especially by screening libraries, by chemical synthesis, or alternatively by mixed methods including chemical or enzymatic modification of sequences obtained by
15 screening libraries. It is preferably cDNA or gDNA.

More preferred therapeutic products include in the case of Parkinson's disease the cDNA encoding tyrosine hydroxylase (TH) or a neurotrophic factor such as BDNF (brain derived neurotrophic factor) which favor the survival of dopaminergic neurons.

- Similarly, for Alzheimer's disease, the cDNA encoding choline acetyl
20 transferase and/or NGF (nerve growth factor) could prevent degeneration of cholinergic neurons.

Recent findings suggest that neurotrophic factors like BDNF and GDNF can be trophic factors for dopaminergic cells. Introduction into astrocytes of genetic material encoding neurotrophic factors are expected to improve graft survival.

- 25 Several adenovirus vectors encoding therapeutic genes have now been constructed. For instance, an adenovirus encoding tyrosine hydroxylase (TH) has been constructed. The grafting of *in vitro* infected astrocytes according to the invention constitutes a very efficient way to deliver therapeutic amounts of TH in the brain. Other adenovirus-derived vectors encoding therapeutic genes include Ad-aFGF, Ad-bFGF, Ad-
30 GDNF, Ad-GAD.

The genetic material of interest can also be an antisense-RNA or ribozyme or a DNA molecule encoding said antisense-RNA or ribozyme. These products are of

particular interest for inhibiting production of toxic proteins such as β -amyloid precursor, TAU proteins, etc.

Preferably, the genetic material is a DNA encoding a protein or peptide of interest. As indicated above, said protein or peptide is preferably a neuroactive substance
5 such as a growth factor (i.e. a cytokine) a neurotrophic factor, an enzyme or a neurotransmitter.

In an other embodiment, the genetic material is a DNA encoding an antisense-RNA or a ribozyme

10 Regulatory Regions

Generally, the nucleic acids of the present invention are linked to one or more regulatory regions. Said regions can include a regulatable or inducible promoter; neural cell-specific promoter, or viral promoter. Selection of the appropriate regulatory region or regions is a routine matter, within the level of ordinary skill in the art.

15 The regulatory regions may comprise a promoter region for functional transcription in astrocytes, as well as a region situated in 3' of the gene of interest, and which specifies a signal for termination of transcription and a polyadenylation site. All these elements constitute an expression cassette.

Promoters that may be used in the present invention include both constitutive
20 promoters and regulated (inducible) promoters. The promoter may be naturally responsible for the expression of the nucleic acid. It may also be from a heterologous source. In particular, it may be promoter sequences of eucaryotic or viral genes. For example, it may be promoter sequences derived from the genome of the cell which it is desired to infect. Likewise, it may be promoter sequences derived from the genome of a
25 virus, including the adenovirus used. In this regard, there may be mentioned, for example, the adenovirus E1A or major late promoter (MLP), a cytomegalovirus (CMV) promoter or a Rous Sarcoma Virus (RSV) promoter.

In addition, the promoter may be modified by addition of activating or regulatory sequences or sequences allowing a tissue-specific or predominant expression (enolase
30 and GFAP promoters and the like). Moreover, when the nucleic acid does not contain promoter sequences, it may be inserted, such as into the virus genome downstream of such a sequence.

Some promoters useful for practice of this invention are ubiquitous promoters (e.g. HPRT, vimentin, actin, tubulin), intermediate filament promoters (e.g. desmin, neurofilaments, keratin, GFAP), therapeutic gene promoters (e.g. MDR type, CFTR, factor VIII), tissue-specific promoters (e.g. actin promoter in smooth muscle cells),
5 promoters which are preferentially activated in dividing cells, promoters which respond to a stimulus (e.g. steroid hormone receptor, retinoic acid receptor), tetracycline-regulated transcriptional modulators, cytomegalovirus immediate-early, retroviral LTR, metallothionein, SV-40, E1a, and MLP promoters. Tetracycline-regulated transcriptional modulators and CMV promoters are described in WO 96/01313, US
10 5,168,062 and 5,385,839, the contents of which are incorporated herein by reference.

Pharmaceutical Administration

15 The present invention enables purification and amplification of adult human astrocytes, and their use for the successful delivery of genes *in vitro* with high efficiency. These cells can then be administered to the CNS of recipient organisms. The invention thereby provides important clinical and scientific applications, such as treatment of trauma to the CNS and of neurodegenerative disorders.

20 The process according to the present invention enables one to target precisely a particular region of the CNS, such as a site within the brain, depending on the transferred therapeutic gene and the disorder to be treated. Thus, according to the site of the impairment to be treated, the administration is made into sites of the brain including, for instance, the striatum, hippocampus or substantia nigra. Preferably, they are grafted in
25 the striatum.

According to the present invention, it is now possible, by stereotactic injection, to deliver astrocytes for engraftment. Determination of the coordinates for administration would be based on the disorder to be treated, and would be determined by the skilled practitioner. The actual therapeutic regimen, including site of injection(s), number and
30 schedule of injections, and particular dosage(s), would also be determined by the skilled practitioner. In general, the number of cells engrafted at a site will be between 1×10^3 and 1×10^{10} , preferably 1×10^3 to 1×10^9 , and more preferably 1×10^6 to 1×10^8 .

It is also an object of the invention to provide an implant comprising astrocyte cells as described above. Preferably, the implant contains non-cellular material increasing survival and in vivo proliferation and differentiation of the cells. The implant can contain for instance collagen, gelatin, fibronectin, lectins, bio-compatible supports such as bone or polytetrafluoroethylen fibers, etc). The invention also concerns a method for the delivery of a therapeutic product to the CNS of a recipient comprising grafting into the brain of said recipient genetically-modified human astrocytes containing introduced genetic material encoding said therapeutic product.

The invention provides safe, non toxic, long term expression of therapeutic genes in vivo. The invention is of particular interest in the treatment of neurodegenerative disorders such as neuropathies, strokes, spinal cord injury, amyotrophic lateral sclerosis, Huntington's chorea, Alzheimer's and Parkinson's diseases, cerebral palsy, epilepsy, lysosomal diseases (e.g. Tay Sachs and Sandhoff diseases, metachromatic leucodystrophy, Gaucher's disease, mucopolysaccharidosis, Lesh Nyhan, etc) as well as brain tumours.

The present invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention.

Examples

The present invention will be described in greater detail with the aid of the following examples which should be considered as illustrative and nonlimiting. Example 1 describes a cell culture protocol enabling the recovery of long-term, pure primary cultures of human adult astrocytes. Example 2 demonstrates that these cells can be genetically modified by using an adenoviral vector encoding human tyrosine hydroxylase (TH) under the control of the tetracycline-based (tet-off) regulatory system (Gossen and Bujard, 1992). TH is the rate limiting enzyme for the synthesis of catecholamines, by converting tyrosine to L-Dopa. Several studies have demonstrated its therapeutic potential in animal model of Parkinson's disease (Wolff et al., 1989;

Horellou et al., 1990a,b; Fisher et al., 1991). Infected cells produced large amounts of active hTH in the absence of doxycycline, a potent analog of tetracycline.

General Molecular Biology

- 5 In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein
- 10 "Sambrook et al., 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II (D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* [B.D. Hames & S.J. Higgins eds. (1985)]; *Transcription And Translation* [B.D. Hames & S.J. Higgins, eds. (1984)]; *Animal Cell Culture* [R.I. Freshney, ed. (1986)]; *Immobilized Cells And Enzymes* [IRL Press, (1986)]; B. Perbal, *A Practical*
- 15 *Guide To Molecular Cloning* (1984); F.M. Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc. (1994).

Example 1: Explantation and characterization of primary cultured human adult astrocytes

20 1.1 Cell culture

- Adult human tissue was isolated from the cerebral cortex of patients (average age 51.5 ± 16.8 years old) undergoing surgical resections, with the consent of the patient, according to the policy of the hospital. Immediately after surgery, the tissue was mechanically dissociated and centrifuged in DMEM/F12 (Sigma) containing D-glucose
- 25 (3.15 g/l), HEPES (3.57 g/l), sodium bicarbonate (1.2 g/l), and supplemented with 10% fetal calf serum (FCS, Seromed), 2 mM glutamine (Gibco), antibiotics (penicillin/streptomycin mix, 100 μ g/ml, Gibco) and fungizone (Gibco), pH 7.4. The pellet was resuspended in the same medium and plated in a 5 cm culture flask (Costar). Cultures were maintained at 37°C in a humidified atmosphere containing 10% CO₂.
- 30 Forty-eight hours later, the medium was changed. These primary cultures were maintained by changing the medium once a week thereafter.

As freezing/thawing procedures, confluent cells were harvested with 0.25% trypsin and 0.2% EDTA (Gibco) and rapidly washed with phosphate buffered saline (PBS, 0.1 M, pH 7.4) to remove the medium-containing serum. The cells were then frozen first at -20°C and finally stored at -80°C in DMEM/F12 supplemented with 10% dimethylsulfoxide (DMSO, Sigma). Cells were thawed by placing the vial in a water bath at 40°C for 2-4 minutes. and replated in a Costa culture flask. Forty-eight hours later, the medium was replaced to eliminate DMSO.

1.2 *Assessment of cell proliferation*

Two different methods were used: direct counting under phase-contrast in a predetermined area of 2 mm² and GFAP-bromodeoxyuridine labeling (BrdU, an analog of thymidine which is only incorporated into replicating DNA) revealed with a double immunofluorescence protocol. Primary cultured cells were plated onto NUNC™ Petri dishes (60x15 mm) with grids (2 mm²) in DMEM/F12.

The proliferation rate was determined under various culture conditions: (a) without FCS, (b) with 10% FCS, (b) 20% FCS, (c) 10% FCS and 5% horse serum (HS), (d) 10% FCS and 10% HS, (e) NGF (50 ng/ml, Sigma), (f) bFGF (50 ng/ml, Boehringer-Mannheim). For proliferation experiments, the medium was changed twice a week. All cultures were counted every 10 hours for 80 hours. The activity of the NGF and bFGF used was ascertained by bioassay: the neuritic extension of PC12 cells (cultured on polyornithine-coated dishes in RPMI supplemented with 10% HS and 5% FCS) exposed to NGF (50 ng/ml), and the differentiation of neuroepithelial progenitor cells in the presence of bFGF (10 ng/ml in DMEM/HAMF12 (see refs in Sabate et al., 1995).

For BrdU incorporation experiments. BrdU was added to primary cultures 2 days post-plating. Cultures were incubated in the presence of 5 or 10 µM BrdU for 4 days. The BrdU treatment was performed simultaneously on 3T3 and 293 cells as proliferation controls. The positive cells were detected by immunocytochemistry, as indicated below.

1.3 *Immunocytochemical procedures*

Cells in primary cultures were rapidly rinsed in PBS, incubated in a fixative solution (4% paraformaldehyde in PBS) for 10 min at room temperature. After rinses in PBS, the cells were treated with a blocking solution (10% goat serum and 0.2% Triton

X-100 in PBS) for 30 min at room temperature, and then incubated with the primary polyclonal antibody (GFAP, Dakopatts, 1:100; S100 β , Sigma, diluted 1:100; TH, Inst. J. Boy, diluted 1:200; BrdU, Jackson, 1:50; OX42, Cedarlane, 1:200) containing 5% goat serum and 0.1% Triton X-100 in PBS.

- 5 For BrdU immunodetection, the cells were first denatured in 2N HCl for 20 min, at room temperature. After neutralization in 0.1N sodium borate for 10 min, the samples were rinsed in PBS and processed as described for GFAP immunocytochemistry.

1.4 Characterization of cultured astrocytes

- 10 To assess the potential of human adult astrocytes for autologous transplantation into the CNS, it was first necessary to test whether these cells can be maintained as primary cultures. Previous studies reported that primary cultures of human adult astrocytes were enriched in microglial cells (Yong et al., 1991, 1992). The composition of the medium and the times between tissue resection, dissociation and cell seeding were
15 varied in order to optimize the culture procedures to obtain astrocyte-enriched preparations. DMEM supplemented with serum is an appropriate culture medium for rodent astroglial cultures. Enriched DMEM supplemented with fetal calf serum (FCS) and with HAM/F12 nutrients was used for astrocyte cultures. The first cells to attach to the culture dish after dissociation and seeding are astrocytes. Various lag times (24-120
20 hours) until the first change of medium containing unattached and/or dead cells and cell debris were tested. A 48 hour (2 days) delay was optimal for obtaining essentially pure astroglial cultures. Surprisingly, microglial cells do not attach to the culture dish under these conditions.

- After two days in DMEM/F12 supplemented with 10% FCS, cells were flattened
25 in the culture dish. Although cell morphology depended on culture confluence, the large majority of cells exhibited a flat polygonal morphology (Figures 1A-B). The flattened cells were identified by immunodetection of astroglial markers including GFAP, the major gliofilament protein, and S100 β , a cytoplasmic calcium-binding protein (Figure 2). Virtually all the primary cultured cells were GFAP- (Figure 2A) and S100 β -positive
30 (Figure 2B). The presence of microglial cells in the cultures was tested by OX42 immunostaining and labeling with B₄ isolectin from *Griffonia simplicifolia*, which is used as a specific marker for microglial cells (Streit, 1990). No staining was observed,

confirming the presence of a culture of astrocytes essentially free of microglial cells. Taken together, these results show that the present invention provides an essentially pure culture of human adult astrocytes. Microscopic inspection of the cultures revealed that many GFAP-positive cells were in mitosis (Figure 1B).

5

1.4.1 *In vitro* proliferation of human adult astrocytes

Preliminary observations indicated that without FCS, none or few of the cultured cells were dividing, whereas mitotic profiles were often observed when 10% FCS was added to the DMEMF12 medium. Double immunofluorescent labeling of GFAP and BrdU revealed that the dividing cells were astrocytes. The capacity of primary cultured human adult astrocytes to proliferate in various culture conditions was analyzed. Soluble molecules including the trophic factors NGF and bFGF, and serum of various species have mitogenic properties on cultured rodent and human fetal astrocytes (see refs in Yong et al., 1991, 1992, and Stachowiak et al., 1997). The effects of various combinations, including FCS, HS, bFGF and NGF, on cell proliferation was tested: 0, 10 and 20% FCS, 10% FCS supplemented with 5 or 10% HS, DMEM supplemented with 50 ng/ml bFGF, DMEM supplemented with 50 ng/ml NGF (Figures 3A-B). Twelve hours after seeding in the presence of FCS, the cells attached and flattened onto the dish surface. Cells only proliferated in the presence of FCS (Figure 3A), and proliferation was maximum at 20% FCS. When cultured in the presence of 10% or 20 % FCS, the astroglial population doubled in 40 hours and 20 hours respectively (Figure 3A). The rate of cell proliferation in the presence of 20% FCS is suitable for cell transplantation, enabling the recovery of $1-5 \times 10^6$ human adult astrocytes within one month from a single biopsy.

Surprisingly, the addition of NGF or bFGF (50 ng/ml medium) did not accelerate the proliferation of human adult astrocytes (Figure 3B). When cultured with FCS supplemented with 5 or 10% HS, most of the human adult astrocytes did not attach to the culture dish and remained in the medium. Nevertheless, a few spherical cells attached but did not flatten onto the culture dish. From 3 days post-plating, some of the attached cells flattened and proliferated very slowly (Figure 3B). In summary, human adult astrocytes can be expanded *in vitro* in the presence of FCS. Twenty percent FCS enables the recovery of a large number of cells suitable for cell transplantation.

30

1.4.2 Cell characterization following freezing/thawing procedures

A patient may receive more than one transplant. Therefore, one issue in the development of autologous grafting in humans is the cryopreservation of primary cultured astrocytes from a single biopsy. Human adult astroglial cells were tested for growth after freezing/thawing procedures. At the first passage, corresponding to 3-4 weeks *in vitro* in DMEM/F12 supplemented with 10% FCS, cultured cells were frozen and kept at -80°C for 2-6 months. Then, cells were rapidly thawed and seeded in DMEM/F12 supplemented with 10% FCS. Cells were carefully observed daily. Ten hours after thawing and seeding, the cells attached and flattened onto the culture dish. They exhibited similar morphological and immunocytochemical features as cells which had not been subjected to freezing procedures. GFAP and S100 β immunostaining confirmed that these cells conserved their astroglial phenotype. During the first day post-plating, the cells did not proliferate. Between day 2 and day 3, the first mitotic profiles were observed. Then, the cell expansion accelerated, and the mean division time was 60 hours in the presence of 10% FCS (Figure 3A). Therefore, human adult astrocytes obtained according to the present invention maintain their capacity to divide following freezing/thawing procedures.

Example 2. Genetic modification of cultured astrocytes

2.1. Adenoviral vectors

25

Adenoviral vectors represent efficient tools to transfer foreign genes to nerve cells as shown by recent studies where direct intracerebral injection to rodent brain provides gene therapy of the central nervous system (WO94/08026). In order to amplify the number of cells suitable for grafting, the inventors have demonstrated that recombinant adenoviruses can efficiently allow gene transfer to cultured human astrocytes.

30

Many Adenovirus-derived vectors have been disclosed in the literature and can be prepared by one skilled in the art. Such vectors can be used in the present invention. (see in particular EP 185 573, Perricaudet et al., FEBS Letters 267 (1990) 60; Levrero et al, Gene 101 (1991) 195, FR 9305954, FR9308596, WO94/12649). An Ad.RSV β gal
5 vector has previously been disclosed in the literature. See for example Stratford-Perricaudet et al. (*J.Clin.Invest.* 90, 626-630 (1992)). This vector contains the E.coli LacZ gene inserted in an adenovirus Ad5 deleted for the E1 and E3 regions.

10 2.2 *Infection of human adult astrocytes with AdPGKtet hTH-1*

Cells were seeded on 6 well culture plates at a density of 6×10^4 cells/well in DMEM/F12 without serum (FCS). Then, the cells were incubated for 4-6 hours with AdPGKtet hTH-1, in which a human tyrosine hydroxylase gene (hTH-1) is under the
15 control of the tetracycline-based "tet-off" regulatory system (Gossen and Bujard, 1992). The hTH gene and the transactivator are driven respectively by a minimal CMV and phosphoglycerate kinase (PGK) promoter. Different multiplicities of infection (MOI) were tested (75, 150 and 300 pfu/cells). Doxycycline was added to the culture medium to a final concentration of 10 ng/ml. The medium was renewed every second day.

20

2.3 *Assessment of TH activity and L-Dopa production by transduced human adult astrocytes*

Three, 7 and 14 days after infection, cells were harvested and processed to
25 measure TH activity and evaluate L-Dopa production. TH activity of cell pellets was assayed as previously described (Reinhard et al., 1986). The production of L-Dopa was assessed after growing human astrocytes for 24 h in DMEM/F12 without FCS. Conditioned media was collected, and 0.5 ml aliquots were mixed with an alumina suspension (40 mg/ml) in 0.05 M Tris-HCl, pH 8.6. Each mixture was then continuously
30 stirred for 10 min, washed with the Tris-HCl buffer, and the alumina finally collected by centrifugation (800 g, 5 min, 4°C). Catechols adsorbed onto the alumina gel were eluted with 0.6 N perchloric acid (0.1 ml per sample), and the eluate was neutralized with 2 M

potassium phosphate pH 7.4 (20 μ l per sample). After centrifugation (30 000 g, 15 min, 4°C), 10 μ l aliquots of the cleared supernatant were injected into a high performance liquid chromatography column (Ultrasphere IP, 25 cm, 0.46 cm outer diameter, 5 μ m) for the electrochemical quantification of L-Dopa, as described in detail elsewhere (Adrien et al., 1989).

2.4 *Result of Genetic engineering of human adult astrocytes*

Cultured human adult astrocytes can be modified by a recombinant adenoviral vector. Optimal transduction is obtained by infecting the cells with a viral preparation of 300 pfu/cell for 6 hours. No obvious toxicity was observed. Fifty-60% of the cells were hTH-positive as assessed by immunocytochemistry (Figures 3A-B). An enzymatic assay developed by Reinhard and colleagues (1986) was used to test whether the hTH was active 3, 7 and 14 days post-infection. TH activity was detectable 3 days after infection (1,290 pmol/mg prot/h), and higher on days 7 (19,000 pmol/mg prot/h) and 14 (35,650 pmol/mg prot/h). In addition, HPLC assays showed that TH-transduced human astrocytes produced 1 μ g L-Dopa /10⁶ cells/24 h, 14 days-post-infection.

To test the efficacy of the tetracycline-based regulatory system, the astroglial cultures were treated with doxycycline (10 ng/ml), a potent analog of tetracycline. Doxycycline efficiently reduced TH expression. TH activity was decreased by at least 10 fold in the presence of doxycycline on day 14 (3,590 pmol/mg prot/h in doxycycline-treated cells vs 35,650 pmol/mg prot/h in untreated cultures) (Figure 4). This indicated that the hTH-1 expression was efficiently controlled by doxycycline. However, as shown on Figure 4, in doxycycline-treated astrocytes, the level of TH activity did not return to baseline. This observation suggested that the minimal promoter P*hCMV, which drives the expression of hTH-1 in the AdPGKtet hTH-1 vector, has a basal activity in the primary cultured human adult astrocytes. Indeed, previous studies report activation of a hCMV promoter in astrocytes under certain experimental conditions, such as after injury, suggesting a environmental regulation of hCMV promoter (McCarthy et al., 1995; Fritschy et al., 1996).

2.5 *Use of other vectors*

As indicated above, other types of vectors can be used to genetically modify the
5 astrocytes according to the invention. This can be viral or non-viral (chemical) vectors.
Preferred viral vectors include AAV, retroviruses, herpes viruses and vaccinia virus. Non
viral vectors include Calcium-phosphate precipitation, liposome-mediated transfection,
cationic lipid transfection and lipopolyamine-mediated transfection.

10

All the references discussed herein are incorporated by reference.

One skilled in the art will readily appreciate the present invention is well adapted
to carry out the objects and obtain the ends and advantages mentioned, as well as those
inherent therein. The peptides, polynucleotides, methods, procedures and techniques
15 described herein are presented as representative of the preferred embodiments, and
intended to be exemplary and not intended as limitations on the scope of the present
invention. Changes therein and other uses will occur to those of skill in the art which are
encompassed within the spirit of the invention or defined by the scope of the appended
claims.

20

REFERENCES

- ADRIEN, J., LANFUMEY, L., GOZLAN, H., FATTACCINI, C.M., and HAMON, M.
(1989). Biochemical and electrophysiological evidence for an agonist action of CM
5 57493 at pre- and post-synaptic 5-HT_{1A} receptors in brain. *J. Pharmacol. Exp. Ther.*
248, 1222-1230.
- ALOISI, F., BORSELLINO, G., SAMOGGIA, P., TESTA, U., CHELUCCI, C.,
RUSSO, G., PESCHLE, C. LEVI, G. (1992). Astrocyte cultures from human
embryonic brain: characterization and modulation of surface molecules by
10 inflammatory cytokines. *J. Neurosci. Res.* **32**, 494-506.
- AUBERT, I., RIDET, J.L., and GAGE, F.H. (1995). Regeneration in the adult
mammalian CNS: guided by development. *Curr. Opin. Neurobiol.* **5**, 625-635.
- BILANG-BLEUEL, A., REVAH, F., COLIN, P., LOCQUET, I., ROBERT, J.J.,
MALLET, J. and HORELLOU, P. (1997). Intrastriatal injection of an adenoviral
15 vector expressing GDNF prevents dopaminergic neuron degeneration and behavioral
impairment in a rat model of Parkinson's disease. *Proc. Natl. Acad. Sci. USA* **94**,
8818-8823.
- CASTILLO Jr., B., DEL CERRO, M., BREAKFIELD, X.O., FRIM, D.M.,
BARNSTABLE, C.J., DEAN, D.O., and BOHN, M.C. (1994). Retinal ganglion cell
20 survival is promoted by genetically modified astrocytes designed to secrete brain-
derived neurotrophic factor (BDNF). *Brain Res.* **647**, 30-37.
- CORTI, O., HORELLOU, P., COLIN, P., CATTANEO, E., and MALLET, J. (1996).
Intracerebral tetracycline-dependent regulation of gene expression in grafts of neural
precursors. *NeuroReport* **7**, 1655-1659.
- 25 CUNNINGHAM, L.A., HANSEN, J.T., SHORT, M.P., and BOHN, M.C. (1991). The
use of genetically altered astrocytes to provide nerve growth factor (NGF) to adrenal
chromaffin cell grafted into the striatum. *Brain Res.* **561**, 192-202.
- CUNNINGHAM, L.A., SHORT, M.P., BREAKFIELD, X.O., and BOHN, M.C. (1994).
Nerve growth factor released by transgenic astrocytes enhanced the function of
30 adrenal chromaffin cell grafts in a rat model of Parkinson's disease. *Brain Res.* **558**,
219-223.

- FISHER, L.J., and GAGE, F.H. (1993). Grafting in the mammalian central nervous system. *Physiol. Rev.* **73**, 583-616.
- FISHER, L.J. (1997). Neural precursor cells: applications for the study and repair of the central nervous system. *Neurobiol. Dis.* **4**, 1-22.
- 5 FISHER, L.J., JINNAH, H.A., KALE, L.C., HIGGINS, G.A., and GAGE, F.H. (1991). Survival and function of intrastrially grafted fibroblasts genetically modified to produce L-DOPA. *Neuron* **6**, 371-380.
- FRITSCHY, J.M., BRANDNER, S., AGUZZI, A., KOEDOOD, M., LUSCHER, B., and MITCHELL, P.J. (1996). Brain cell type specificity and gliosis-induced activation of
10 the human cytomegalovirus immediate-early promoter in transgenic mice. *J. Neurosci.* **16**, 2275-82.
- GAGE, F.H., RAY, J., and FISHER, L.J. (1995). Isolation, characterization and use of stem cells from the CNS. *Ann. Rev. Neurosci.* **18**, 159-192.
- GOODMAN, J.C., TRASK, T.W., CHEN, S.H., WOO, S.L.C, GROSSMAN, R.G.,
15 CAREY, K.D., HUBBARD, G.B., CARRIER, D.A., RAJAGOPALAN, S., AGUILAR-CORDOVA, E., and SHINE, H.D. (1996). Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies. *Human Gene Ther.* **7**, 1241-1250.
- 20 GOSSEN, M., and BUJARD, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc. Natl. Acad. Sci. USA* **89**, 5547-5551.
- GOSSEN, M., FREUNDLIEB, S., BENDER, G., MULLER, G., HILLEN, W., and BUJARD, H. (1995). Transcriptional activation by tetracyclines in mammalian cells.
25 *Science* **268**, 1766-1769.
- HORELLOU, P., BRUNDIN, P., KALEN, P., MALLET, J., and BJÖRKLUND, A. (1990a). In vivo release of DOPA and dopamine from genetically engineered cells grafted to the denervated striatum. *Neuron* **5**, 393-402.
- HORELLOU, P., MARLIER, L., PRIVAT, A., and MALLET, J. (1990b). Behavioral
30 effect of engineered cells that synthesize L-Dopa or dopamine after grafting into the rat neostriatum. *Eur. J. Neurosci.* **2**, 116-119.

- HORELLOU, P., VIGNE, E., CASTEL, M.N., BARNEOUD, P., COLIN, P., PERRICAUDET, M., DELAERE, P. and MALLET, J. (1994). Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. *NeuroReport* **6**, 49-53.
- 5 JUORIO, A.V., LI, X.M., WALZ, W., and PATERSON, I.A. (1993). Decarboxylation of L-dopa by cultured mouse astrocytes. *Brain Res.* **626**, 306-309.
- KISTNER, A., GOSSEN, M., ZIMMERMANN, F., JERECIC J., ULLMER, C., LUBBERT, H., and BUJARD, H. (1996). Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. *Proc. Natl. Acad. Sci.*
- 10 USA **93**, 10933-10938.
- KOJIMA, H., ABIRU, Y., SAKAJIRI, K., WATABE, K., OHISHI, N., TAKAMORI, M., HATANAKA, H., and YAGI, K. (1997). Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain.
- 15 Biochem. Biophys. Res. Commun. **238**, 569-573.
- LA GAMMA, E.F., WIESINGER, G., LENN, N.J., and STRECKER, R.E. (1993). Genetically modified primary astrocytes as cellular vehicles for gene therapy in the brain. *Cell Transplant.* **2**, 207-214.
- LEVALLOIS, C., MALLET, J., and PRIVAT, A. (1996). An adenovirus vector
- 20 encoding tyrosine hydroxylase activity may enter human CNS cells in primary dissociated cultures. *Int. J. Dev. Neurosci.* **14**, 613-619.
- LIN, Q., CUNNINGHAM, L.A., EPSTEIN, L.G., PECHAN, P.A., SHORT, M.P., FLEET C., and BOHN, M.C. (1997). Human fetal astrocytes as an ex vivo gene therapy vehicle for delivering biologically active nerve growth factor. *Hum. Gene*
- 25 Ther. **8**, 331-339.
- LUNDBERG, C., HORELLOU, P., MALLET, J., and BJÖRKLUND, A. (1996). Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: *in vitro* characterization and *in vivo* effects in the rat Parkinson model. *Exp. Neurol.* **139**, 39-53.
- 30 MARON, A., HAVAUX, N., LE ROUX, A., KNOOPS, B., PERRICAUDET, M., and OCTAVE, J.N. (1997). Differential toxicity of ganciclovir for rat neurons and

astrocytes in primary culture following adenovirus-mediated transfer of the HSVtk gene. *Gene Ther.* **4**, 25-31.

MARTINEZ-SERRANO, A., and BJORKLUND, A. (1997). Immortalized neural progenitor cells for CNS gene transfer and repair. *Trends Neurosci.* **20**, 530-538.

- 5 McCARTHY, M., WOOD, C., FEDOSEYEVA, L., and WHITTEMORE, S.C. (1995). Media components influence viral gene expression assays in human fetal astrocyte cultures. *J. Neurovirol.* **1**, 275-285.

MILLER, N., and WHELAN, J. (1997) Progress in transcriptionally targeted and regulatable vectors for genetic therapy. *Hum. Gene Ther.* **8**, 803-815.

- 10 OLANOW, C.W., KORDOWE, J.H., and FREEMAN, T.B. (1996). Fetal nigral transplantation as a therapy for Parkinson's disease. *Trends Neurosci.* **19**, 102-109.

PERZELOVA, A. and MARES, V. (1993). Appearance of GFAP-positive cells in adult human brain cultures spontaneously decelerated in growth. *Glia* **7**, 237-244.

- 15 PUNDT, L.L., KONDOH, T., and LOW, W.C. (1995). The fate of human glial cells following transplantation in normal rodents and rodent models of neurodegenerative disease. *Brain Res.* **695**, 25-36.

REINHARD Jr, J.F., SMITH, G.K., and NICHOL, C.A. (1986). A rapid and sensitive assay for tyrosine-3-monooxygenase based upon the release of $^3\text{H}_2\text{O}$ and adsorption of [^3H]-tyrosine by charcoal. *Life Sci.* **39**, 2185-2189.

- 20 RIDET, J.L., MALHOTRA, S.K., PRIVAT, A., and GAGE, F.H. (1997). Reactive astrocytes: cellular and molecular cues to biological function. *Trends Neurosci.* **20**, 570-577.

- 25 RIDOUX, V., ROBERT, J.J., ZHANG, X., PERRICAUDET, M., MALLET, J., and LEGAL LA SALLE, G. (1994). The use of adenovirus vectors for intracerebral grafting of transfected nervous cells. *NeuroReport* **5**, 801-804.

SABATE, O., HORELLOU, P., VIGNE, E., COLIN, P., PERRICAUDET, M., BUC-CARON, M.H., and MALLET, J. (1995). Transplantation to the rat brain of human neural progenitors that were genetically modified using adenovirus. *Nature Genet.* **9**, 256-260.

- 30 SAEZ, E., NO, D., WEST, A., and EVANS, R.M. (1997) Inducible gene expression in mammalian cells and transgenic mice. *Curr. Opin. Biotechnol.* **8**, 608-616.

- SHOCKETT, P., DIFILIPPANTONIO, M., HELLMAN, N., and SCHATZ, D.G. (1995). A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. *Proc. Natl. Acad. Sci. USA* **92**, 6522-6526.
- 5 STACHOWIAK, M.K., MOFFETT, J., MAHER, P., TUCHOLSKI J., and STACHOWIAK, E.K. (1997). Growth factor regulation of cell growth and proliferation in the nervous system. *Mol. Neurobiol.* **15**, 257-283.
- STREIT, W.J. (1990). An improved staining method for rat microglial cells using the lectin from *Griffonia simplicifolia* (GSA I-B4). *J. Histochem. Cytochem.* **38**, 1683-1686.
- 10 TAYLOR, R. (1997). Cell vehicles for gene transfer to the brain. *Neuromuscul. Dis.* **7**, 343-351.
- WOLFF J.F., FISHER, L.J., XU, L., JINNAH, H.A., LANGLAIS, P.J., IUVONE, P.M., O'MALLEY, K.L., ROSENBERG, M.B., SHIMOHAMA, S., FRIEDMANN, T., and GAGE, F.H. (1989). Grafting fibroblasts genetically modified to produce L-Dopa in a rat model of Parkinson's disease. *Proc. Natl. Acad. Sci. USA* **86**, 9011-9014.
- 15 YONG, V.W., MOUMDJIAN, R., YONG, F.P., RUIJS, T.C.G., FREEDMAN, M.S., CASHMAN, N., and ANTEL, J.P. (1991). Gamma-interferon promotes proliferation of adult human astrocytes in vitro and reactive gliosis in the adult mouse brain in vivo. *Proc. Natl. Acad. Sci. USA* **88**, 7016-7020.
- 20 YONG, V.W., TEJADA-BERGES, T., GOODYER, C.G., ANTEL, J.P., and YONG, F.P. (1992). Differential proliferative response of human and mouse astrocytes to gamma-interferon. *Glia* **6**, 269-280.
- YOSHIMOTO, Y., LIN, Q., COLLIER, T., FRIM, D., BREAKFIELD, X.O., and BOHN, M.C. (1995). Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. *Brain Res.* **691**, 25-36.
- 25

CLAIMS

1. A method of producing an essentially pure population of astrocytes, the method comprising
- 5 a) introducing a preparation of astrocytes to a culture vessel,
b) incubating the astrocytes from step a) under conditions enabling attachment of the astrocytes to the culture vessel, and
c) removing cells which have not attached to the culture vessel at a time of about 48 hours from the beginning of step a).
- 10 2. The method according to claim 1, wherein the astrocytes are human astrocytes.
3. The method according to claim 2, wherein the human astrocytes are human adult astrocytes.
- 15 4. The method according to claim 1, wherein said essentially pure population of astrocytes is essentially free of microglial cells.
5. The method according to claim 1, wherein the astrocytes are primary astrocytes
- 20 obtained by surgical resection from a patient.
6. The method according to claim 1, wherein unattached cells are removed from the culture vessel by a change of culture media.
- 25 7. The method according to claim 1, further comprising a step d) of introducing a nucleic acid into the astrocytes.
8. The method according to claim 7, wherein the nucleic acid is introduced into the astrocytes with a viral vector.
- 30 9. The method according to claim 8, wherein the viral vector is selected from the group consisting of adenovirus, Herpes virus, AAV, retrovirus and vaccinia virus.

10. The method according to claim 9, wherein the viral vector is a replication defective adenoviral vector.
- 5 11. The method according to claim 7, wherein the nucleic acid is introduced into the astrocytes by calcium-phosphate precipitation, liposome-mediated transfection, cationic lipid transfection, or lipopolyamine-mediated transfection.
12. The method according to claim 7, wherein the nucleic acid encodes a neuroactive
10 substance.
13. An essentially pure population of astrocytes produced by the method according to claim 1.
- 15 14. An essentially pure population of astrocytes.
15. The population of astrocytes according to claim 14, wherein the astrocytes are human astrocytes.
- 20 16. The population of astrocytes according to claim 15, wherein the human astrocytes are human adult astrocytes.
17. The population of astrocytes according to claim 16, wherein said population of astrocytes is essentially free of microglial cells.
- 25 18. The population of astrocytes according to claim 14, wherein the astrocytes are primary astrocytes obtained by surgical resection from a patient.
19. The population of astrocytes according to claim 14, further comprising an
30 exogenous nucleic acid.

20. The population of astrocytes according to claim 19, wherein the nucleic acid is introduced into the astrocytes with a viral vector.

21. The population of astrocytes according to claim 20, wherein the viral vector is
5 selected from the group consisting of adenovirus, Herpes virus, AAV, retrovirus and vaccinia virus.

22. The population of astrocytes according to claim 21, wherein the viral vector is a replication defective adenoviral vector.

10

23. The population of astrocytes according to claim 19, wherein the nucleic acid is introduced into the astrocytes by calcium-phosphate precipitation, liposome-mediated transfection, cationic lipid transfection, or lipopolyamine-mediated transfection.

15 24. The population of astrocytes according to claim 19, wherein the nucleic acid encodes a neuroactive substance.

25. The population of astrocytes according to claim 19, wherein said nucleic acid is DNA or RNA.

20

26. The population of astrocytes according to claim 25, wherein said nucleic acid is a DNA encoding a protein, polypeptide or peptide.

27. The population of astrocytes according to claim 26, wherein said protein,
25 polypeptide or peptide is selected from the group consisting of growth factors, neurotrophic factors, and enzymes.

28. The population of astrocytes according to claim 25, wherein said nucleic acid is a DNA encoding an antisense-RNA or a ribozyme.

30

29. The population of astrocytes according to claim 24, wherein said nucleic acid is operably linked to a regulatory region.

30. The population of astrocytes according to claim 29, wherein the regulatory region comprises a regulatable promoter, an inducible promoter, a neural cell-specific promoter or a viral promoter.

5

31. An implant comprising a population of astrocytes according to claim 14.

32. A composition comprising an essentially pure population of astrocytes comprising an exogenous nucleic acid encoding a neuroactive substance.

10

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190



Figure 1A




Figure 1B

2/5



Figure 2A



Figure 2B




Figure 3A




Figure 3B




Figure 4A



Figure 4B



Figure 4C

5/5





Figure 5

**DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION**

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s).
I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Human Adult Astrocytes, Their Preparation and Uses Thereof

and the specification of which (check one) ☐ is attached hereto (Attorney Docket No. _____)
☒ was filed on **13 June 2001** as U.S. Application Number **09/868,026**
and was amended on _____ (if applicable).
☐ was described and claimed in PCT Int'l Application Number _____ filed on _____
and as amended under PCT Article 19 on _____ (if any).

I/We hereby state that I/We have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above.

I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56.

☐ I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Foreign Priority: Number _____ Country _____ Day/Month/Year Filed _____

Prior Foreign Appn(s): Number _____ Country _____ Day/Month/Year Filed _____

☒ I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below:

60/114,758 **05 January 1999**
Number Filing Date

☒ I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

PCT/IB00/00615 **05 January 2000** **Pending**
Application Serial No. Filing Date Status (Patented, Pending)

I/We hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as my/our attorneys and/or agents with full power to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Customer No.: 005487

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventors(s): ☐ Additional names and signatures are attached.

1. Full name: **Jean-Luc Ridet**

Signature: Jean Luc Ridet

Date: October 18, 01

Country of Citizenship: France

Residence: Lausanne, Switzerland CHX
(City and State/City and Country only)

P. O. Address: Route d'Oron 77/514, CH-1010
Lausanne, Switzerland

2. Full name: **Jacques Mallet**

Signature: Jacques Mallet

Date: October 18, 01

Country of Citizenship: France

Residence: Paris, France FLX
(City and State/City and Country only)

P. O. Address: 18, rue Charcot, F-75013
Paris, France

3. Full name: _____

Signature: _____

Date: _____

Country of Citizenship: _____

Residence: _____
(City and State/City and Country only)

P. O. Address: _____

4. Full name: _____

Signature: _____

Date: _____

Country of Citizenship: _____

Residence: _____
(City and State/City and Country only)

P. O. Address: _____

5. Full name: _____

Signature: _____

Date: _____

Country of Citizenship: _____

Residence: _____
(City and State/City and Country only)

P. O. Address: _____

6. Full name: _____

Signature: _____

Date: _____

Country of Citizenship: _____

Residence: _____
(City and State/City and Country only)

P. O. Address: _____

7. Full name: _____

Signature: _____

Date: _____

Country of Citizenship: _____

Residence: _____
(City and State/City and Country only)

P. O. Address: _____

8. Full name: _____

Signature: _____

Date: _____


Country of Citizenship: _____

Residence: _____
(City and State/City and Country only)

P. O. Address: _____

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code EMC-G1
Bridgewater, NJ 08807-0800
Telephone (908) 231-
Telefax (908) 231-2626

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not
present
for scanning. (Document title)

☒ *Scanned copy is best available. drawing is dark*